Photo of Andrew Hantel, MD, MPH

Andrew Hantel, MD, MPH

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute

Photo of Andrew Hantel, MD, MPH

Dana-Farber Cancer Institute

Visualize Collaborations

Andrew Hantel, MD, MPH

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Assistant Professor, Medicine, Harvard Medical School

HCC PROGRAM AFFILIATION

Research Abstract

Andrew Hantel, M.D., I am a hematologic oncologist at Dana-Farber Cancer Institute (DFCI) and an Assistant Professor of Medicine at Harvard Medical School (HMS). As an investigator in the Divisions of Population Sciences and Leukemia at DFCI, my research program leverages health services methods to advance clinical trial participation, results generalizability, and related aspects of care delivery. I also provide clinical care for patients with leukemia and serve as a hospital ethics consultant at DFCI, and I hold a co-appointment at the HMS Center for Bioethics. I have received career development awards from the National Cancer Institute (K08) and American Society of Clinical Oncology (ASCO) to characterize multilevel mediators of barriers to leukemia research participation and develop interventions to remediate them. I am also PI on a Leukemia and Lymphoma Society award assessing the effectiveness and implementation of a multilevel intervention on underrepresented patient participation in blood cancer clinical trials. Aligned projects I am leading with the Alliance for Clinical Trials in Oncology (ACTO) and Break Through Cancer seek to better match trial eligibility criteria and dose modifications to anticipated drug safety while lowering participant burdens. Finally, I am PI on a multicenter pragmatic clinical trial testing the safety and efficacy of Duffy null-specific dose modifications for standard-of-care chemotherapy regimens. My research program is closely linked with my administrative roles as a member on the Ethics Committees at ASCO and ATCO, the ACTO Health Disparities and Leukemia Committees liaison, and a subcommittee chair for DFCIs Clinical Trials Access Committee. I am also committed to mentorship and provide career guidance and research oversight to trainees in graduate medical and bioethics education on related projects.

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Hantel A, Walsh TP, Li KY, Awan S, Littlejohn E, Lathan CS, Abel GA. The Trial Enrollment Diversity Dashboard for Acute Leukemia Clinical Research: Intervention Development and Cohort Analysis. JCO Oncol Pract 2024. PubMed
  • Hibbs SP, Aiken L, Vora K, Mowete C, Merz LE, Apea V, Sloan JM, Lathan CS, Abel GA, Hantel A. Cancer Trial Eligibility and Therapy Modifications for Individuals With Duffy Null-Associated Neutrophil Count. JAMA Netw Open 2024; 7:e2432475. PubMed
  • Koranteng E, Cernik C, Gallagher E, Hantel A, Marron J, Abel G. Clinical ethics consultation services: public-facing information on NCI-designated cancer center websites. Oncologist 2024. PubMed
  • Hantel A, Cernik C, Walsh TP, Uno H, Larios D, Slutzman JE, Abel GA. Assessing the Environmental and Downstream Human Health Impacts of Decentralizing Cancer Care. JAMA Oncol 2024. PubMed
  • Patel K, Ivanov A, Jocelyn T, Hantel A, Garcia JS, Abel GA. Patient-Reported Outcomes in Phase 3 Clinical Trials for Blood Cancers: A Systematic Review. JAMA Netw Open 2024; 7:e2414425. PubMed
  • Hantel A, Marron JM, Abel GA. Establishing and Defining an Approach to Climate Conscious Clinical Medical Ethics. Am J Bioeth 2024. PubMed
  • Hantel A, Spence R, Camacho P, Bradbury AR, Denburg AE, Jagsi R, Moy B, Rathmell WK, Rosenberg AR, Symington B, Marron JM, Peppercorn J. ASCO Ethical Guidance for the Practical Management of Oncology Drug Shortages. J Clin Oncol 2024; 42:358-365. PubMed
  • Hantel A, Cernik C, Uno H, Walsh TP, Calip GS, DeAngelo DJ, Lathan CS, Abel GA. Sociodemographic associations with uptake of novel therapies for acute myeloid leukemia. Blood Cancer J 2023; 13:192. PubMed
  • Kelkar AH, Hantel A, Koranteng E, Cutler CS, Hammer MJ, Abel GA. Digital Health to Patient-Facing Artificial Intelligence: Ethical Implications and Threats to Dignity for Patients With Cancer. JCO Oncol Pract 2023. PubMed
  • Hantel A, Luskin MR, Khan I, Warner E, Patel AA, Walsh TP, DeAngelo DJ, Lathan CS, Abel GA. Use, variability, and justification of eligibility criteria for phase II and III clinical trials in acute leukemia. Haematologica 2023. PubMed
  • Lichter KE, Weinstein HNW, Husain M, Kishan R, Hantel A, Maniar A. National Cancer Institute Centers With Environmental Sustainability Plans for Climate Change. JAMA Netw Open 2023; 6:e2317206. PubMed
  • Rebechi M, Kohlschmidt J, Mrózek K, Nicolet D, Mims AS, Blachly JS, Orwick S, Larkin K, Oakes CC, Hantel A, Carroll AJ, Blum W, Powell BL, Uy GL, Stone RM, Larson RA, Byrd JC, Paskett ED, Plascak JJ, Eisfeld AK. Association of social deprivation with survival in younger adult patients with AML: an Alliance study. Blood Adv 2023. PubMed
  • Marron JM, Hantel A, Abel GA, Peppercorn JM. Ethics Consultation in Oncology: The Search for Quality in Quantity. JCO Oncol Pract 2022. PubMed
  • Hantel A, Clancy DD, Kehl KL, Marron JM, Van Allen EM, Abel GA. A Process Framework for Ethically Deploying Artificial Intelligence in Oncology. J Clin Oncol 2022. PubMed
  • Hantel A, Kohlschmidt J, Eisfeld AK, Stock W, Jacobson S, Mandrekar S, Larson RA, Stone RM, Lathan CS, DeAngelo DJ, Byrd JC, Abel GA. Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention. J Clin Oncol 2022. PubMed
  • Hantel A, McManus ML, Wadleigh M, Cotugno M, Abel GA. Impact of Allocation on Survival During Intermittent Chemotherapy Shortages: A Modeling Analysis. J Natl Compr Canc Netw 2022; 20:335-341.e17. PubMed
  • Hantel A, Luskin MR, Garcia JS, Stock W, DeAngelo DJ, Abel GA. Racial and ethnic enrollment disparities and demographic reporting requirements in acute leukemia clinical trials. Blood Adv 2021; 5:4352-4360. PubMed
  • Abel GA, Klepin HD, Magnavita ES, Jaung T, Lu W, Shallis RM, Hantel A, Bahl NE, Dellinger-Johnson R, Winer ES, Zeidan AM. Peri-transfusion quality-of-life assessment for patients with myelodysplastic syndromes. Transfusion 2021. PubMed
  • Abel GA, Kim HT, Hantel A, Steensma DP, Stone R, Habib A, Ho VT, Wadleigh M, El-Jawahri A, Alyea EP, DeAngelo DJ, Koreth J, Antin JH, Soiffer RJ, Cutler C. Author Correction: Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? Leukemia 2021. PubMed
  • Hantel A, Peppercorn J, Abel GA. Model solutions for ethical allocation during cancer medicine shortages. Lancet Haematol 2021; 8:e246-e248. PubMed
  • Hantel A, Marron JM, Casey M, Kurtz S, Magnavita E, Abel GA. US State Government Crisis Standards of Care Guidelines: Implications for Patients With Cancer. JAMA Oncol 2021; 7:199-205. PubMed
  • Hantel A, DuMontier C, Odejide OO, Luskin MR, Sperling AS, Hshieh T, Chen R, Soiffer R, Driver JA, Abel GA. Gait speed, survival, and recommended treatment intensity in older adults with blood cancer requiring treatment. Cancer 2020. PubMed
  • Abel GA, Kim HT, Hantel A, Steensma DP, Stone R, Habib A, Ho VT, Wadleigh M, El-Jawahri A, Alyea EP, DeAngelo DJ, Koreth J, Antin JH, Soiffer RJ, Cutler C. Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? Leukemia 2020. PubMed
  • Hantel A, Abel GA. An Action Plan for Environmentally Sustainable Cancer Care. JAMA Oncol 2020. PubMed
  • Hantel A, Egan AM, Nguyen TT, DeMartino ES, Hlubocky F, Bastow S, Siegler M, Daugherty CK. A Cross-Sectional Survey of Medical Trainee Experiences During Medication Shortages. J Grad Med Educ 2020; 12:38-43. PubMed
  • Hantel A, Hlubocky FJ, Siegler M, Daugherty CK. A Qualitative Analysis of Oncology Patient Awareness of Medication Shortages and Their Preferences for How Shortages Should Be Managed. JCO Oncol Pract 2020; 16:e1098-e1111. PubMed
  • Hantel A, Abel GA, Siegler M. Practical allocation system for the distribution of specialised care during cellular therapy access scarcity. J Med Ethics 2019. PubMed
  • Hantel A, Siegler M, Hlubocky F, Colgan K, Daugherty CK. Prevalence and Severity of Rationing During Drug Shortages: A National Survey of Health System Pharmacists. JAMA Intern Med 2019; 179:710-711. PubMed
  • Balagopal V, Hantel A, Kadri S, Steinhardt G, Zhen CJ, Kang W, Wanjari P, Ritterhouse LL, Stock W, Segal JP. Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing. PLoS ONE 2019; 14:e0224097. PubMed
  • Hantel A, Levine S, Siegler M. Creating Coherent Strategies to Combat the Crises of Opioid Scarcity and Abuse. J Clin Oncol 2018; 36:2575-2577. PubMed
  • Bestvina CM, Wroblewski KE, Daly B, Beach B, Chow S, Hantel A, Malec M, Huber MT, Polite BN. A Rules-Based Algorithm to Prioritize Poor Prognosis Cancer Patients in Need of Advance Care Planning. J Palliat Med 2018; 21:846-849. PubMed
  • Hantel A, Stock W, Kosuri S. Molecular Minimal Residual Disease Testing in Acute Myeloid Leukemia: A Review for the Practicing Clinician. Clin Lymphoma Myeloma Leuk 2018; 18:636-647. PubMed
  • Hantel A, Gabster B, Cheng JX, Golomb H, Gajewski TF. Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab. J Immunother Cancer 2018; 6:73. PubMed
  • Hantel A, Larson RA. Imatinib is still recommended for frontline therapy for CML. Blood Adv 2018; 2:3648-3652. PubMed
  • Khan N, Hantel A, Knoebel RW, Artz A, Larson RA, Godley LA, Thirman MJ, Liu H, Churpek JE, King D, Odenike O, Stock W. Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia. Leuk Lymphoma 2017; 58:1-7. PubMed
  • Welch JS, Petti AA, Miller CA, Fronick CC, O'Laughlin M, Fulton RS, Wilson RK, Baty JD, Duncavage EJ, Tandon B, Lee YS, Wartman LD, Uy GL, Ghobadi A, Tomasson MH, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Cashen AF, Schroeder MA, Jacoby MA, Heath SE, Luber K, Janke MR, Hantel A, Khan N, Sukhanova MJ, Knoebel RW, Stock W, Graubert TA, Walter MJ, Westervelt P, Link DC, DiPersio JF, Ley TJ. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. N Engl J Med 2016; 375:2023-2036. PubMed
  • Daly B, Hantel A, Wroblewski K, Balachandran JS, Chow S, DeBoer R, Fleming GF, Hahn OM, Kline J, Liu H, Patel BK, Verma A, Witt LJ, Fukui M, Kumar A, Howell MD, Polite BN. No Exit: Identifying Avoidable Terminal Oncology Intensive Care Unit Hospitalizations. J Oncol Pract 2016; 12:e901-e911. PubMed
  • Hantel A, Olopade CO. Drug and vaccine access in the Ebola epidemic: advising caution in compassionate use. Ann Intern Med 2015; 162:141-2. PubMed
  • Marquez R, Hantel A, Lorenz R, Neistadt B, Wong J, Churpek JE, Mardini NA, Shaukat I, Gurbuxani S, Miller JL, Godley LA. A new family with a germline ANKRD26 mutation and predisposition to myeloid malignancies. Leuk Lymphoma 2014; 55:2945-6. PubMed
  • Hantel A. A protocol and ethical framework for the distribution of rationed chemotherapy. J Clin Ethics 2014; 25:102-15. PubMed
  • Nabhan C, Smith SM, Helenowski I, Ramsdale E, Parsons B, Karmali R, Feliciano J, Hanson B, Smith S, McKoy J, Larsen A, Hantel A, Gregory S, Evens AM. Analysis of very elderly (≥80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome. British Journal of Haematology 2012; 156:196-204. PubMed
Hide
Visualize Collaborations